Vincent Lo Re III, MD, MSCE

Office Location836, Blockley Hall
Office Phone215-573-5964
Emailvincentl@mail.med.upenn.edu

Faculty Information

CCEB AppointmentSenior Scholar, Epidemiology
Primary Faculty AppointmentAssistant Professor of Medicine, Division of Infectious Diseases, University of Pennsylvania Perelman SOM
DBE AppointmentAssistant Professor of Epidemiology

Research Statement

Dr. Lo Re is an Infectious Diseases physician and clinical epidemiologist whose area of interest is HIV-viral hepatitis coinfection. Dr. Lo Re’s research has focused on the clinical outcomes of chronic viral hepatitis infection and its treatment in the HIV population. Recently, he has examined the incidence and risks factors for weight loss during HIV/hepatitis C therapy. He is currently examining novel risk factors for end-stage liver disease among HIV/hepatitis-coinfected patients in two national HIV cohorts – the Veterans Aging Cohort Study and the Women’s Interagency HIV Study. Another aim of this grant is to develop and internally validate a clinical predictive index to stratify HIV/hepatitis C-coinfected patients according to their risk of progression to hepatic decompensation.

Dr. Lo Re has also conducted research examining adherence to pegylated interferon and ribavirin hepatitis C therapy, specifically examining the levels of adherence required for maximal hepatitis C suppression and risk factors for poor adherence to these therapies.

Dr. Lo Re is also interested in HIV/hepatitis B virus coinfection. Recent work in this area has focused on the prevalence, risk factors, and clinical significance of occult hepatitis B virus infection in HIV-infected patients.

Dr. Lo Re is also interested in epidemiologic methods research, particularly examining optimal methods to ascertain viral hepatitis-associated clinical outcomes in ongoing cohort studies.

Courses Taught

Course Director, Biostatistics for Epidemiologic Methods Laboratory (EPID 526-527)
Lecturer, Epidemiological Methods in Infectious Diseases (EPID 656)
Lecturer, GI Epidemiology (EPID 658)

Selected Publications

Lo Re V 3rd, Kallan MJ, Tate J, AR Localio, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC: Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. Ann Intern Med Page: In Press, Feb 2014.

Lim JK, Tate J, Fultz SL, Goulet JL, Rimland D, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Fiellin DA, Justice AC, Lo Re V 3rd: Relationship between alcohol use categories and advanced hepatic fibrosis in HIV-infected and uninfected patients. Clin Infect Dis Page: In Press, Feb 2014.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd: Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. J Hepatol Page: In Press, Feb 2014.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd: Prevalence of diagnosed chronic hepatitis B infection among U.S. Medicaid enrollees, 2000 – 2007. Ann Epidemiol Page: In Press, Feb 2014.

Lo Re V 3rd, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KBF, Hennessy S, Reddy KR, Pawloski PA, Daniel GW, Cheetham TC, Iyer A, Coughlin KO, Toh S, Boudreau DM, Cooper WO, Selvam N, Selvan MS, VanWormer JJ, Avigan MI, Houstoun M, Zornberg GL, Racoosin JA, Shoaibi A: Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacepidemiol Drug Saf(22), 861-72, May 2013.

Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd: Incidence and risk factors for incomplete hepatitis B virus DNA suppression in HIV/hepatitis B-coinfected patients receiving tenofovir-based antiretroviral therapy. J Viral Hepat Page: In Press, June 2013.

Lo Re V 3rd, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, Kostman JR, Tebas P, Leonard MB, Localio AR : Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/HIV coinfection. Hepatology 56: 1688-98, Oct 2012.

Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R: Relationship between adherence to hepatitis C virus therapy and virologic outcomes. Ann Intern Med 155(6): 353-60, Sept 2011.

Lo Re V 3rd, Lim JK, Goetz MB, Tate J, Bathulapalli H, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Kidwai F, Brandt C, Dorey-Stein Z, Reddy KR, Justice AC: Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 20(7): 689-99, July 2011.

Lo Re V 3rd, Guaraldi G, Leonard MB, Lin J, Orlando G, Squillace N, Rochira V, Giovanni C, Kostman JR, Tebas P: Viral hepatitis coinfection is associated with reduced bone mineral density in HIV-infected women but not men. AIDS 23(16): 2191-8, Oct 2009.



Penn Medicine CCEB Home